W E Truog1, L D Nelin2, A Das3, D E Kendrick3, E F Bell4, W A Carlo5, R D Higgins6, A R Laptook7, P J Sanchez8, S Shankaran9, B J Stoll10, K P Van Meurs11, M C Walsh12. 1. Center for Infant Pulmonary Disorders, Children's Mercy Hospitals and Clinics and the University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. 2. Department of Pediatrics, Nationwide Children's Hospital, Ohio State University School of Medicine, Columbus, OH, USA. 3. Statistics & Epidemiology Unit, RTI International, Rockville, MD, USA. 4. Department of Pediatrics, University of Iowa, Iowa City, IA, USA. 5. Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL, USA. 6. Eunice Kennedy Shriver National Institute of Health & Human Development, National Institutes of Health, Bethesda, MD, USA. 7. Department of Pediatrics, Women & Infants' Hospital, Brown University School of Medicine, Providence, RI, USA. 8. Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 9. Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA. 10. Department of Pediatrics, Emory University School of Medicine & Children's Healthcare of Atlanta, Atlanta, GA, USA. 11. Department of Pediatrics, Stanford University School of Medicine, Palo, Alto, CA, USA. 12. Department of Pediatrics, Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, OH, USA.
Abstract
OBJECTIVE: The use of inhaled nitric oxide (iNO) in preterm infants remains controversial. In October 2010, a National Institutes of Health consensus development conference cautioned against use of iNO in preterm infants. This study aims (1) to determine the prevalence and variability in use of iNO in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) before and after the consensus conference and (2) separately, to examine associations between iNO use and severe bronchopulmonary dysplasia (BPD) or death. STUDY DESIGN: The NICHD NRN Generic Database collects data including iNO use on very preterm infants. A total of 13 centers contributed data across the time period 2008 to 2011. Infants exposed or not to iNO were compared using logistic regression, which included factors related to risk as well as their likelihood of being exposed to iNO. RESULT: A total of 4885 infants were assessed between 2008 and 2011; 128 (2.6%) received iNO before day 7, 140 (2.9%) between day 7 and 28, and 47 (1.0%) at >28 days. Center-specific iNO use during 2008 to 2010 ranged from 21.9 to 0.4%; 12 of 13 sites reduced usage and overall NRN iNO usage decreased from 4.6 to 1.6% (P<0.001) in 2011. The use of iNO started between day 7 and day 14 was more prevalent among younger infants with more severe courses in week 1 and associated with increased risk of severe BPD or death (odds ratio 2.24; 95% confidence interval 1.23 to 4.07). CONCLUSION: The variability and total use of iNO decreased in 2011 compared with 2008 to 2010. iNO administration started at ⩾ day 7 was associated with more severe outcomes compared with infants without iNO exposure.
OBJECTIVE: The use of inhaled nitric oxide (iNO) in preterm infants remains controversial. In October 2010, a National Institutes of Health consensus development conference cautioned against use of iNO in preterm infants. This study aims (1) to determine the prevalence and variability in use of iNO in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NICHD NRN) before and after the consensus conference and (2) separately, to examine associations between iNO use and severe bronchopulmonary dysplasia (BPD) or death. STUDY DESIGN: The NICHD NRN Generic Database collects data including iNO use on very preterm infants. A total of 13 centers contributed data across the time period 2008 to 2011. Infants exposed or not to iNO were compared using logistic regression, which included factors related to risk as well as their likelihood of being exposed to iNO. RESULT: A total of 4885 infants were assessed between 2008 and 2011; 128 (2.6%) received iNO before day 7, 140 (2.9%) between day 7 and 28, and 47 (1.0%) at >28 days. Center-specific iNO use during 2008 to 2010 ranged from 21.9 to 0.4%; 12 of 13 sites reduced usage and overall NRN iNO usage decreased from 4.6 to 1.6% (P<0.001) in 2011. The use of iNO started between day 7 and day 14 was more prevalent among younger infants with more severe courses in week 1 and associated with increased risk of severe BPD or death (odds ratio 2.24; 95% confidence interval 1.23 to 4.07). CONCLUSION: The variability and total use of iNO decreased in 2011 compared with 2008 to 2010. iNO administration started at ⩾ day 7 was associated with more severe outcomes compared with infants without iNO exposure.
Authors: Jean-Christophe Mercier; Helmut Hummler; Xavier Durrmeyer; Manuel Sanchez-Luna; Virgilio Carnielli; David Field; Anne Greenough; Bart Van Overmeire; Baldvin Jonsson; Mikko Hallman; James Baldassarre Journal: Lancet Date: 2010-07-23 Impact factor: 79.321
Authors: Krisa P Van Meurs; Linda L Wright; Richard A Ehrenkranz; James A Lemons; M Bethany Ball; W Kenneth Poole; Rebecca Perritt; Rosemary D Higgins; William Oh; Mark L Hudak; Abbot R Laptook; Seetha Shankaran; Neil N Finer; Waldemar A Carlo; Kathleen A Kennedy; Jon H Fridriksson; Robin H Steinhorn; Gregory M Sokol; G Ganesh Konduri; Judy L Aschner; Barbara J Stoll; Carl T D'Angio; David K Stevenson Journal: N Engl J Med Date: 2005-07-07 Impact factor: 91.245
Authors: Michael R Stenger; Jonathan L Slaughter; Kelly Kelleher; Edward G Shepherd; Mark A Klebanoff; Patricia Reagan; Leif D Nelin; William Gardner Journal: Pediatrics Date: 2012-03-12 Impact factor: 7.124
Authors: K Murthy; N F M Porta; J M Lagatta; I Zaniletti; W E Truog; T R Grover; L D Nelin; R C Savani Journal: J Perinatol Date: 2017-02-09 Impact factor: 2.521
Authors: Abhik Das; Jon Tyson; Claudia Pedroza; Barbara Schmidt; Marie Gantz; Dennis Wallace; William E Truog; Rosemary D Higgins Journal: Semin Perinatol Date: 2016-06-22 Impact factor: 3.300
Authors: S C Handley; R H Steinhorn; A O Hopper; B Govindaswami; D R Bhatt; K P Van Meurs; R L Ariagno; J B Gould; H C Lee Journal: J Perinatol Date: 2016-03-31 Impact factor: 2.521